市場調査レポート

商品コード

1800999

病院感染治療薬の市場レポート：薬剤タイプ、適応症、地域別、2025～2033年

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 445,411円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 593,931円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 742,451円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.52円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の病院感染治療薬市場規模は2024年に131億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに196億米ドルに達し、2025年から2033年にかけて4.32%の成長率（CAGR）を示すと予測しています。多剤耐性感染症の増加、抗菌薬スチュワードシップの重視、研究開発（R&D）の継続的な進展、世界のヘルスケア支出の増加とインフラ整備は、市場成長に影響を与える主な要因の一部です。

病院感染治療薬市場動向：

院内感染（HAI）の増加

病院感染治療薬市場の主な促進要因の1つは、HAIの発生率の上昇です。これらの感染症には細菌性、ウイルス性、真菌性などがあり、侵襲的な医療処置や手術、医療機器の使用に関連することが多いです。HAIの蔓延は世界的に大きな問題となっており、こうした感染症を管理・治療するための効果的な治療薬に対する需要の高まりにつながっています。これに加えて、ヘルスケア環境内での薬剤耐性病原体の蔓延は、高度で的を絞った治療オプションの必要性をさらに高めており、これらの感染症と効果的に闘うための革新的で強力な治療薬の開発が必要とされています。

抗菌薬管理プログラムに対する意識の高まり

抗菌薬スチュワードシップ・プログラムは、抗菌薬耐性の出現と蔓延に対抗するための重要な戦略として注目を集めています。これらのプログラムは、耐性菌の発生を最小限に抑えつつ、患者の転帰を改善するために抗菌薬の使用を最適化することに重点を置いています。抗菌薬スチュワードシップに対する意識の高まりから、薬剤耐性病原体がもたらす特有の課題に対処できる新規治療薬の開発と導入が重視されるようになり、市場開拓に明るい見通しが生まれています。さらに、世界中の様々なヘルスケア組織や規制機関が、抗生物質やその他の抗菌剤の適切な使用を確保するために、抗菌薬スチュワードシップを積極的に推進しており、市場拡大に弾みをつけています。

研究開発活動の著しい進歩

感染症分野における継続的な研究開発活動は、病院感染治療薬市場の拡大に大きく貢献しています。これに伴い、ゲノム学、微生物学、免疫学の進歩により、感染症のメカニズムや新規創薬ターゲットの同定に関する貴重な知見が得られています。新たな抗菌化合物の発見や併用療法の開発が市場拡大に寄与しています。これに加え、製薬企業、学術機関、研究機関の広範な協力関係が、モノクローナル抗体、ワクチン、新規抗生物質などの革新的な治療法の発見と開発を後押しし、市場の成長を後押ししています。

ヘルスケア支出の増加とインフラ開発

世界のヘルスケア支出の増加とヘルスケア分野のインフラ開拓の進展が、病院感染治療薬市場の成長を促進しています。これと同時に、多くの政府や民間投資家が病院やクリニックなどのヘルスケア施設の拡張や近代化に投資しています。このため、HAIの発生を管理・抑制するための効果的なツールを医療提供者に提供するための感染症治療薬の需要が高まり、市場の成長が加速しています。さらに、新興国におけるヘルスケア・インフラの拡大が、病院感染治療薬の新たな市場を開拓しています。ヘルスケアへのアクセスが改善するにつれて、感染症に関連するヘルスケアの課題に対処するための高度な治療オプションに対する需要が急増しています。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第9章 SWOT分析

第10章バリューチェーン分析

第11章ポーターのファイブフォース分析

第12章価格分析

第13章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Allergan Plc（AbbVie Inc.）
- AstraZeneca Plc
- Bayer Aktiengesellschaft
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG（Roche Holding AG）
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi S.A.

図表

List of Figures

Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2024
Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2024
Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2024
Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 5: Global: Hospital Infection Therapeutics Market Structure
Table 6: Global: Hospital Infection Therapeutics Market: Key Players

Product Code: SR112025A2393

The global hospital infection therapeutics market size reached USD 13.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 19.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.32% during 2025-2033. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Trends:

Increasing incidence of hospital-acquired infections (HAIs):

One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.

Growing awareness of antimicrobial stewardship programs

Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.

Significant advancements in R&D activities

Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.

Rising healthcare expenditure and infrastructure development

The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.

Hospital Infection Therapeutics Industry Segmentation:

Breakup by Drug Type:

Anti-bacterial Drugs
Anti-fungal Drugs
Anti-viral Drugs
Others

Anti-bacterial drugs accounts for the majority of the market share

The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.

In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.

Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.

Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.

Breakup by Indication:

Blood Stream Infections
Urinary Tract Infections
Surgical Site Infections
Pneumonia
Others

Surgical site infections holds the largest share of the industry

The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.

The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.

Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.

Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.

Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.

Moreover, North America's robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.

Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.

Besides this, Latin America's evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.

Leading Key Players in the Hospital Infection Therapeutics Industry:

The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Allergan Plc (AbbVie Inc.)
AstraZeneca Plc
Bayer Aktiengesellschaft
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG (Roche Holding AG)
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc
Pfizer Inc.
Sanofi S.A.

Key Questions Answered in This Report:

How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
What are the key regional markets?
Which countries represent the most attractive hospital infection therapeutics market?
What is the breakup of the market based on the drug type?
Which is the most attractive drug type in the hospital infection therapeutics market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the hospital infection therapeutics market?
What is the competitive structure of the market?
Who are the key players/companies in the global hospital infection therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Type

6.1 Anti-bacterial Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Anti-fungal Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Anti-viral Drugs
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Indication

7.1 Blood Stream Infections
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Urinary Tract Infections
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Surgical Site Infections
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Pneumonia
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Allergan Plc (AbbVie Inc.)
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 AstraZeneca Plc
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 Bayer Aktiengesellschaft
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 Bristol-Myers Squibb Company
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 SWOT Analysis
- 13.3.6 Gilead Sciences Inc.
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 GlaxoSmithKline Plc
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 Johnson & Johnson
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
  - 13.3.8.4 SWOT Analysis
- 13.3.9 Merck & Co. Inc.
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
  - 13.3.9.3 Financials
  - 13.3.9.4 SWOT Analysis
- 13.3.10 Pfizer Inc.
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financials
  - 13.3.10.4 SWOT Analysis
- 13.3.11 Sanofi S.A.
  - 13.3.11.1 Company Overview
  - 13.3.11.2 Product Portfolio
  - 13.3.11.3 Financials
  - 13.3.11.4 SWOT Analysis

病院感染治療薬の市場レポート：薬剤タイプ、適応症、地域別、2025～2033年

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2025-2033

病院感染治療薬市場動向：

院内感染（HAI）の増加

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の病院感染治療薬市場

第6章 市場内訳：薬剤タイプ別

第7章 市場内訳：適応症別

第8章 市場内訳：地域別

第9章 SWOT分析

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

第12章 価格分析

第13章 競合情勢